Citadel Advisors’s AnaptysBio ANAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.9M | Buy |
233,450
+123,967
| +113% | +$6.67M | ﹤0.01% | 2880 |
|
|
2025
Q4 | $5.31M | Buy |
109,483
+83,003
| +313% | +$3.24M | ﹤0.01% | 4207 |
|
|
2025
Q3 | $811K | Sell |
26,480
-91,806
| -78% | -$2.11M | ﹤0.01% | 7998 |
|
|
2025
Q2 | $2.63M | Sell |
118,286
-254,283
| -68% | -$5.32M | ﹤0.01% | 5200 |
|
|
2025
Q1 | $6.93M | Buy |
372,569
+198,842
| +114% | +$3.32M | ﹤0.01% | 3378 |
|
|
2024
Q4 | $2.3M | Sell |
173,727
-31,818
| -15% | -$771K | ﹤0.01% | 5338 |
|
|
2024
Q3 | $6.89M | Buy |
205,545
+124,564
| +154% | +$4.26M | ﹤0.01% | 3445 |
|
|
2024
Q2 | $2.03M | Sell |
80,981
-243,764
| -75% | -$5.68M | ﹤0.01% | 5274 |
|
|
2024
Q1 | $7.31M | Buy |
324,745
+209,772
| +182% | +$4.97M | ﹤0.01% | 3382 |
|
|
2023
Q4 | $2.46M | Sell |
114,973
-71,495
| -38% | -$1.23M | ﹤0.01% | 4998 |
|
|
2023
Q3 | $3.35M | Buy |
186,468
+32,339
| +21% | +$617K | ﹤0.01% | 4295 |
|
|
2023
Q2 | $3.13M | Buy |
154,129
+73,910
| +92% | +$1.5M | ﹤0.01% | 4388 |
|
|
2023
Q1 | $1.75M | Sell |
80,219
-200,323
| -71% | -$4.87M | ﹤0.01% | 5642 |
|
|
2022
Q4 | $8.69M | Sell |
280,542
-52,336
| -16% | -$1.48M | ﹤0.01% | 3016 |
|
|
2022
Q3 | $8.49M | Buy |
332,878
+299,103
| +886% | +$7.01M | ﹤0.01% | 3004 |
|
|
2022
Q2 | $686K | Buy |
33,775
+25,059
| +288% | +$555K | ﹤0.01% | 7916 |
|
|
2022
Q1 | $216K | Buy |
+8,716
| New | +$264K | ﹤0.01% | 11338 |
|
|
2021
Q2 | – | Sell |
-37,731
| Closed | -$904K | – | 13604 |
|
|
2021
Q1 | $813K | Sell |
37,731
-770,513
| -95% | -$19.4M | ﹤0.01% | 8609 |
|
|
2020
Q4 | $17.4M | Sell |
808,244
-146,118
| -15% | -$3.55M | ﹤0.01% | 1954 |
|
|
2020
Q3 | $14.1M | Sell |
954,362
-14,468
| -1% | -$261K | ﹤0.01% | 1903 |
|
|
2020
Q2 | $21.6M | Buy |
968,830
+570,951
| +143% | +$10.4M | 0.01% | 1441 |
|
|
2020
Q1 | $5.62M | Buy |
397,879
+373,717
| +1,547% | +$5.67M | ﹤0.01% | 2563 |
|
|
2019
Q4 | $393K | Sell |
24,162
-253,694
| -91% | -$6M | ﹤0.01% | 7177 |
|
|
2019
Q3 | $9.72M | Sell |
277,856
-276,068
| -50% | -$13.1M | ﹤0.01% | 2252 |
|
|
2019
Q2 | $31.3M | Buy |
553,924
+57,857
| +12% | +$4.17M | 0.01% | 1033 |
|
|
2019
Q1 | $36.2M | Buy |
496,067
+23,502
| +5% | +$1.62M | 0.02% | 876 |
|
|
2018
Q4 | $30.1M | Sell |
472,565
-176,895
| -27% | -$13.2M | 0.02% | 923 |
|
|
2018
Q3 | $64.8M | Sell |
649,460
-182,438
| -22% | -$15.1M | 0.03% | 609 |
|
|
2018
Q2 | $59.1M | Buy |
831,898
+531,331
| +177% | +$44.6M | 0.03% | 608 |
|
|
2018
Q1 | $31.3M | Sell |
300,567
-196,202
| -39% | -$22.1M | 0.02% | 830 |
|
|
2017
Q4 | $50M | Sell |
496,769
-87,080
| -15% | -$6.41M | 0.03% | 612 |
|
|
2017
Q3 | $20.4M | Buy |
+583,849
| New | +$15.7M | 0.02% | 1057 |
|
Other funds holding ANAB
EC
TCM
AAA
VCM
PAI
6CM
Citadel Advisors's ANAB Position: Q1 2026 in Review
Citadel Advisors increased its AnaptysBio (ANAB) stake by 113% in Q1 2026, buying an estimated $6.67M and bringing the position to 233,450 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2880.
Citadel Advisors first reported a position in ANAB in Q3 2017 and has held it in 32 quarters since. The position peaked at $64.8M in Q3 2018. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.
- Citadel Advisors held 233,450 shares of AnaptysBio worth $12.9M as of Q1 2026.
- Citadel Advisors bought 123,967 AnaptysBio shares in Q1 2026, an estimated $6.67M.
- AnaptysBio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2880 holding.
- Citadel Advisors first reported a position in AnaptysBio in Q3 2017 and has held it in 32 quarters since.
- Citadel Advisors's AnaptysBio position peaked at $64.8M in Q3 2018.
- 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.